AtriCure, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATRC research report →
Range $50 – $70
Price Chart
About the company
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories.
- CEO
- Michael H. Carrel
- IPO
- 2005
- Employees
- 1,350
- HQ
- Mason, OH, US
Get TickerSpark's AI analysis on ATRC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.82B
- P/E
- 182.85
- Fwd P/E
- 239.52
- PEG
- 0.13
- P/S
- 4.75
- P/B
- 5.04
- EV/EBITDA
- 69.02
- Div Yield
- 0.00%
- Gross Margin
- 76.61%
- Op Margin
- 3.06%
- Net Margin
- 2.52%
- ROE
- 2.93%
- ROIC
- 2.62%
Latest fiscal year · YoY change
- Revenue
- $534.53M+14.9%
- Gross Profit
- $397.74M+14.4%
- Op Income
- $-3,447,000
- Net Income
- $-11,448,000+74.4%
- EPS
- $-0.24+74.7%
- OCF Growth
- +369.8%
- FCF Growth
- +529.0%
- 52W High
- $66.02
- 52W Low
- $25.36
- 50D MA
- $57.65
- 200D MA
- $39.45
- Beta
- 1.21
- RSI (14)
- 45
- Avg Volume
- 1.04M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
AtriCure posted a strong Q3 with 15% revenue growth, expanding margins, and raised full-year EBITDA guidance, while management highlighted product momentum and key clinical catalysts.· November 3, 2026
- Revenue rose to $154.5 million, up 15% year over year, with strength in U.S. open ablation, appendage management, and pain management.
- Gross margin improved to 77.3%, up 180 basis points, and adjusted EBITDA increased 50.6% to $26.8 million.
- Full-year 2026 guidance was raised for adjusted EBITDA to $91 million to $94 million, while revenue is now expected at $606 million to $610 million.
- EnCompass Clamp, AtriClip FLEX/PRO-Mini, cryoSPHERE MAX, and cryoXT all saw strong adoption; cryoXT sales topped $1 million for the first time.
- Management continues to see headwinds in international markets and U.S. hybrid ablation, but remains confident in the long-term pipeline and clinical trial catalysts.
Third-quarter 2026 revenue was $154.5 million, up 15.0% reported and 15.1% in constant currency versus Q3 2025. U.S. revenue was $128 million, up 17.1% year over year, while international revenue was $26.4 million, up 5.8% reported and 6.1% in constant currency. Gross margin was 77.3%, up 180 basis points from the prior year period. Net income was $4.1 million versus a net loss of $0.3 million a year ago; adjusted EBITDA was $26.8 million versus $17.8 million, up 50.6%; EPS was $0.08 and adjusted EPS was $0.18. For full year 2026, AtriCure now expects revenue of approximately $606 million to $610 million, gross margin in the upper 76% range, adjusted EBITDA of approximately $91 million to $94 million, EPS of approximately $0.21 to $0.27, and adjusted EPS of approximately $0.40 to $0.46.
Mike Carrel said the quarter reflected broad-based momentum and improving profitability, with growth led by innovation and adoption across the portfolio. He emphasized EnCompass Clamp adoption, the expanding evidence base behind open ablation and AtriClip, and the upcoming STS quality metric as important demand drivers. He also framed BoxX-NoAF and LeAAPS as major long-term catalysts that could expand the addressable market in cardiac surgery.
Angela Wirick said revenue beat was driven by the U.S. business, especially open ablation at $43 million, appendage management at $51.6 million, and pain management at $28.1 million. She noted gross margin of 77.3% benefited from favorable product and geographic mix, partially offset by new manufacturing facility costs, while operating expenses were $115 million including a $4.5 million PFA milestone payment. She also highlighted $187 million in cash and investments at quarter-end, $19.2 million of cash generated in the quarter, and reiterated that the company expects to generate cash in Q4 while raising full-year adjusted EBITDA guidance.
Analysts focused on whether the STS quality metric and stronger clinical data were already driving more adoption of open ablation, and management said the lift was mainly awareness, evidence, and easier use rather than incremental training. Questions on guidance and margin showed concern about why the full-year outlook did not rise more after the quarter beat; management pointed to prudence, international weakness, and U.S. hybrid ablation headwinds. Analysts also pressed on competition in appendage management and cryoXT ramp; management said AtriCure still has strong field coverage, the smallest clip on the market with more innovation coming, and that cryoXT is progressing as expected with reorders from existing accounts.
The call showed broad operating momentum: 15% revenue growth, 77.3% gross margin, and adjusted EBITDA up more than 50%. Management sounded confident that product innovation, the STS quality metric, and clinical readouts from BoxX-NoAF and LeAAPS can support further growth.
Management repeatedly flagged sustained headwinds in certain international markets and in the U.S. hybrid ablation business. They also signaled that gross margin could step down in Q4 due to a full quarter of new facility costs, and that competition in appendage management is increasing even if AtriCure believes it remains ahead.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.0%
- Shares Outstanding
- 50.92M
- Float Shares
- 48.89M
of shares held by institutions
262 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ATRC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Sell | Sep 29, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Aug 20, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 3, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | May 6, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jul 19, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jun 18, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jun 8, 21 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Apr 30, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 31, 20 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Feb 21, 20 | Filing → |
| Gilbert CisnerosHouse · CA39 | Buy | Nov 7, 19 | Filing → |
| Gilbert CisnerosHouse · CA39 | Buy | Jun 27, 19 | Filing → |
| Gilbert CisnerosHouse · CA39 | Buy | May 8, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 7.94M | ▲ 3.47M |
| Vanguard Group Inc | 4.90M | ▲ 62.86K |
| Wellington Management Group Llp | 4.12M | ▲ 620.60K |
| Vanguard Portfolio Management LLC | 3.63M | ▲ 499.80K |
| Alliancebernstein L.P. | 2.93M | ▲ 157.93K |
| Hood River Capital Management LLC | 2.84M | ▼ 62.75K |
| Vanguard Capital Management LLC | 2.19M | ▲ 3.21K |
| State Street Corp | 2.13M | ▲ 738.82K |
| Nomura Asset Management International Inc. | 1.49M | ▼ 248.13K |
| Geode Capital Management, LLC | 1.30M | ▼ 16.60K |
| Goldman Sachs Group Inc | 1.11M | ▼ 488.58K |
| Dimensional Fund Advisors LP | 1.02M | ▼ 22.82K |
Held by 390 ETFs
Biggest fund positions in ATRC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | JOHNSON B KRISTINE | sell | 2,452 |
| Nov 4, 26 | Privitera Salvatore | sell | 8,404 |
| Sep 23, 26 | Privitera Salvatore | sell | 4,519 |
| Sep 11, 26 | GROVES REGINA E | sell | 5,313 |
| Sep 8, 26 | Privitera Salvatore | sell | 3,657 |
| Sep 2, 26 | Privitera Salvatore | sell | 7,763 |
| Aug 24, 26 | Dahlquist Karl S. | sell | 9,370 |
| Aug 5, 26 | Prange Karen | sell | 3,564 |
| Aug 5, 26 | Yuen Maggie | sell | 3,500 |
| Jul 30, 26 | CARREL MICHAEL H | other | 700 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ATRC coverage
Recent articles, reports, and earnings notes.
No research on ATRC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATRC report →AtriCure to Participate in the Piper Sandler 38th Annual Healthcare Conference
businesswire.com · Nov 17
AtriCure, Inc. (ATRC) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 9
AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy
seekingalpha.com · Nov 8
AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results
benzinga.com · Nov 4
AtriCure, Inc. (ATRC) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
What AtriCure (ATRC) Said on Its Q3 Earnings Call
marketbeat.com · Nov 3
Compared to Estimates, AtriCure (ATRC) Q3 Earnings: A Look at Key Metrics
zacks.com · Nov 3
AtriCure (ATRC) Beats Q3 Earnings and Revenue Estimates
zacks.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.